A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01782313|
Recruitment Status : Active, not recruiting
First Posted : February 1, 2013
Last Update Posted : March 1, 2018
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Adult Soft Tissue Sarcoma Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma||Drug: tivozanib Other: laboratory biomarker analysis||Phase 2|
I. To determine the progression-free survival (defined as complete response [CR] + partial response [PR] + stable disease [SD]) assessed at 16 weeks for patients treated with tivozanib.
I. Overall response rate (defined as CR + PR). II. Clinical benefit rate (CR + PR + SD). III. Overall survival (up to 2 years beyond progression). IV. Correlation of clinical outcome with antibodies for vascular endothelial growth factor receptor 1 (VEGFR1) and VEGFR2.
V. Assess Safety and tolerability.
Patients receive tivozanib orally (PO) daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity, or until discontinuation per patient preference or physician recommendation.
After completion of study treatment, patients are followed up every 3 months for 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||54 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas|
|Study Start Date :||February 2013|
|Estimated Primary Completion Date :||January 2019|
|Estimated Study Completion Date :||August 2020|
Experimental: Treatment (tivozanib)
Patients receive tivozanib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Other Names:Other: laboratory biomarker analysis
- Progression-free survival from study disease will be evaluated using imaging scans (CT or MRI) [ Time Frame: Evaluation takes place after 16 weeks of treatment ]Progression-free survival from study disease will be evaluated using imaging scans (CT or MRI) following 16 weeks of treatment.
- Determine overall response rate [ Time Frame: Every 2 cycles (8 weeks) up to 2 years ]The response to study treatment will be assessed after every 8 weeks (2 cycles) of therapy using CT or MRI scan images.
- Determine the clinical benefit rate [ Time Frame: Every 2 cycles (8 weeks) up to 2 years ]The clinical benefit of study treatment will be assessed after 8 weeks (2 cycles) of therapy using scanning images (CT or MRI).
- Determine overall survival [ Time Frame: Time from the first dose of study treatment up to 2 years beyond disease progression ]Patients will be followed-up with from first dose of study drug up to 2 years following the date of disease progression.
- Evaluate proteins and correlate with response to therapy [ Time Frame: Tissue collected during screening process (prior to study start date) ]Tissue from biopsy will be collected during screening and proteins (VEGFR1 and VEGFR2) will be evaluated to see if there is a correlation with patient response to treatment.
- Treatment toxicity as measured by adverse events experienced while on treatment [ Time Frame: After every 4 weeks (1 cycle) ]Toxicity will be assessed after 4 weeks (1 cycle).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01782313
|United States, Illinois|
|Chicago, Illinois, United States, 60611|
|United States, Iowa|
|University of Iowa|
|Iowa City, Iowa, United States, 52246|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|United States, Missouri|
|Saint Louis, Missouri, United States, 63110|
|United States, Wisconsin|
|University of Wisconsin|
|Madison, Wisconsin, United States, 53792|
|Principal Investigator:||Mark Agulnik, MD||Northwestern University|